ALDARA
LOE ApproachingNDATOPICALCREAM
Approved
Feb 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ALDARA is a topical cream formulation approved in 1997 for treating dermatological conditions. The product is an NDA (New Drug Application) with an unknown mechanism of action and pharmacologic class. It represents a mature therapeutic option in the topical dermatology space.
LOE Approaching
Loss of exclusivity is approaching, signaling potential downsizing of commercial teams and shift toward defensive positioning against generic competition.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
H5N1 With or Without Topical Aldara in Healthy Adults
Started Jun 2018
50 enrolled
Avian InfluenzaInfluenza Immunisation
Career Relevance
Only 2 linked jobs are available for ALDARA, concentrated in R&D Scientist roles, reflecting the product's mature, post-launch stage. This product offers limited career growth opportunities due to its approaching loss of exclusivity and minimal active development.
Scientist
Worked on ALDARA at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.